Plasmodium falciparum protein and nucleic acid synthesis enzymes

Plasmodium falciparum protein and nucleic acid synthesis enzymes represent a diverse group of essential metabolic and replicative catalysts required for the survival and proliferation of the malaria parasite. This category includes enzymes involved in the folate biosynthesis pathway, such as dihydrofolate reductase (DHFR) and dihydropteroate synthase (DHPS), which are critical for DNA synthesis (Gregson & Plowe, 2005, PMID: 16210243). It also encompasses the protein synthesis machinery, including ribosomal subunits and aminoacyl-tRNA synthetases located in the parasite's cytoplasm and its unique organelle, the apicoplast (Bhatt et al., 2022, PMID: 35143461). Drugs targeting these enzymes, such as antifolates (sulfadoxine-pyrimethamine) and antibiotics (clindamycin, doxycycline), disrupt the parasite's ability to replicate its genome and produce necessary proteins, leading to cell death (Dahl & Rosenthal, 2007, PMID: 18045102). However, the rapid emergence of genetic mutations in these enzymes, such as those in the dhfr and dhps genes, poses a significant challenge, leading to widespread drug resistance in endemic regions (White, 2004, PMID: 15175535). From a drug development perspective, these enzymes offer high selectivity due to significant structural differences between plasmodial and human orthologs, particularly within the apicoplast-localized machinery.

Other names

P. falciparum biosynthetic enzymesMalaria parasite translation and transcription machineryPlasmodium falciparum folate and protein synthesis pathways

Inhibition of essential biosynthetic pathways including the folate cycle (nucleic acid precursor synthesis) and the translation machinery (ribosomal function or aminoacyl-tRNA charging) within the parasite or its apicoplast (Dahl & Rosenthal, 2007, PMID: 18045102).